Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Addex Announces Participation in the H.C. Wainwright Global Investment Conference

Addex Announces Participation in the 22nd Bio€quity Europe Conference

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Reports Q1 2022 Financial Results

Addex to Present at the Swiss Biotech Day 2022

Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders